NasdaqGS:ILMNLife Sciences
Illumina (ILMN) Is Up 5.7% After Raising 2026 Revenue Guidance and Q3 Outlook
In late July 2026, Illumina reported second-quarter revenue of US$1,159 million, raised its third-quarter outlook to US$1.14 billion–US$1.16 billion, and increased full-year 2026 revenue guidance to US$4.60 billion–US$4.64 billion from its prior US$4.52 billion–US$4.62 billion range.
The company’s decision to lift guidance, despite lower year-on-year net income and earnings per share, underscores management’s confidence in clinical sequencing demand and expanding NovaSeq X adoption as key...